It has been week to remember, Nordic Biomarker is on a roll. First, the company was awarded the spin-off company of the year at Umeågalan, then they found themselves on Deloitte’s list of the fastest growing tech companies in Sweden.
In a successful study; carried out in collaboration between Pernilla Abrahamsson at MD Biomedical, Senzime, and Umeå University, it is shown that MD Biomedical's microdialysis probe (Onzurf) is able to detect ischemic conditions in the gut. The goal is that the probe shall be used to monitor, and thus be able to prevent complications after surgery.
The onset of the eye disease Glaucoma, can occur at any age, but it becomes more frequent with increasing age. Only half of all patients with Glaucoma are aware of their problems, with a buildup of the fluid pressure in the eye. This is unfortunate since an early discovery, followed by lifelong treatment to reduce the pressure, decrease the risk for loss of eye sight. Alongside the lifelong treatment, follows the need for regular checkups, where the pressure in the eye is monitored.
Umecrine Mood AB announced the final results from an exploratory randomized Phase I/II study with its candidate drug UC1010 in patients with PMDD. The results show a statistically significant improvement of symptoms in patients treated with UC1010 compared to placebo.
Most women experience some form of premenstrual symptoms but in about five percent of young and middle‐aged women that have PMDD, the symptoms are so debilitating that they affect normal daily life, work and relationships. The severity of the symptoms confers huge costs on society.
Swetree Technologies makes a profit, at the same time as the collaboration agreement with more than 30 senior academic scientists is extended and a new share issue is closed netting 16 million SEK.
STT has also started a long term collaboration with Fibria, the largest Eucalyptus bleached pulp producer in the world.
The Swedish pharmaceutical development company Adenovir Pharma, based on research from Umeå, has raised SEK 10 million via a rights issue to fund completion of an ongoing clinical phase II study for treatment of infectious eye disease and to prepare for exit.
ALMI is distributing a limited number of Vinnovas 100 000 SEK innovation checks to SME companies. The purpose with these checks, is to stimulate the development of innovations in small and medium sized companies and at the same time contribute to the innovativeness within these companies.
Does this sound interesting?
130 investors from 11 countries have arrived to STING Day in Stockholm to meet 70 of Sweden’s hottest technology start-ups. Three Umeå-companies are there to make new connections. Two of them are Biotech companies.
Umeå company, AcureOmics AB has received four million in funding from the European Commission for a research project to develop techniques to prevent kidney transplant rejection. The BIOMARGIN project (BIOMArkers of Renal Graft INjuries in kidney allograft recipients) aims to provide more individualized treatments in order to improve patients’ quality of life by increasing long-term survival of the transplanted kidney.
Business Sweden, the Swedish trade and invest council are, in collaboration with partners, arranging the Israeli-Nordic LS Partnering on May 20-22, in conjunction with the annual Biomed Israel Innovation Conference in Tel Aviv. The Biomed Israel Innovation Conference approximately gathers 3000 participants, from over 45 countries.
Umeå based company Betagenon is starting phase I clinical studies with their energy metabolism regulating substance, O304.
Biotech Umeå Investement Day, January 27 2015, Grand Hôtel
Kurs i produktutveckling för medicinteknik och in vitro diagnostik. Delmoment 2
Biotech Umeå, Uminova Innovation
Box 7978, SE-907 19 Umeå